

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: A61K 31/66, 31/685	A1	(11) International Publication Number: WO 96/39150 (43) International Publication Date: 12 December 1996 (12.12.96)
(21) International Application Number: PCT/US96/08361 (22) International Filing Date: 3 June 1996 (03.06.96) (30) Priority Data: 08/471,464 6 June 1995 (06.06.95) US (60) Parent Application or Grant (63) Related by Continuation US 08/471,464 (CON) Filed on 6 June 1995 (06.06.95) (71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): DAIFOTIS, Anastasia, G. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). YATES, Ashley, J. [GB/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).		(81) Designated States: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: BISPHOSPHONATE THERAPY FOR BONE LOSS ASSOCIATED WITH RHEUMATOID ARTHRITIS		
(57) Abstract Bisphosphonates, and particularly alendronate, can prevent or treat bone loss associated with rheumatoid arthritis.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

TITLE OF THE INVENTION

BISPHOSPHONATE THERAPY FOR BONE LOSS ASSOCIATED WITH RHEUMATOID ARTHRITIS

5 SUMMARY OF THE INVENTION

This invention relates to the use of bisphosphonates, particularly alendronate, to prevent bone loss associated with rheumatoid arthritis.

10 BACKGROUND OF THE INVENTION

Rheumatoid arthritis (RA) is a chronic, multisystemic disease of unknown cause. The characteristic feature of RA is persistent inflammatory synovitis, usually involving peripheral joints. One hallmark of the disease is cartilage destruction and periarticular bone erosion caused by synovial inflammation, resulting in joint deformities. The cell believed to be responsible for the erosive process in the osteoclast. In patients with RA, therapy often includes glucocorticoid administration, immobilization of joints, cyclosporine or methotrexate, all of which may potentiate bone loss and deformity.

20 It would be desirable to prevent or treat generalized and periarticular bone loss associated with RA.

DETAILED DESCRIPTION OF THE INVENTION

25 It has been found in accordance with this invention that bisphosphonates can prevent and treat bone loss associated with rheumatoid arthritis when administered in either a prophylactically or therapeutically effective amount.

In particular, alendronate (4-amino-1-hydroxybutylidene-1,1-bisphosphonate) or a pharmaceutically effective salt thereof, can prevent and treat bone loss associated with rheumatoid arthritis when administered either in a prophylactically or therapeutically effective amount.

A further aspect of this invention is a method of preventing or treating generalized and/or periarticular bone loss associated with

- 2 -

rheumatoid arthritis comprising administering an effective amount of a bisphosphonate selected from the group consisting of: alendronate, etidronate (1-hydroxy-ethidene-bisphosphonic acid), pamidronate (3-amino-1-hydroxypropyldiene-1,1-diphosphanate), risedronate
5 (2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonic acid), clodronate (dichloromethylene-bisphosphonic acid), tiludronate (chloro-4-phenylthio-methylidene-bisphosphonic acid), ibandronic acid (1-hydroxy-3(methylpenty-lamino)-propylidene-bisphosphonic acid, and pharmaceutically acceptable salts of any of the foregoing, and mixtures
10 of any of the acids and any of the salts to a patient suffering from rheumatoid arthritis. All of the foregoing compounds are well known in the art.

Generally the patient undergoing treatment for rheumatoid arthritis will be receiving one or more of: an immunosuppressive drug,
15 cyclosporine, methotrexate, or glucocorticoids.

As used throughout the specification and claims, the following definitions apply:

20 "Prophylactically effective amount"--the amount of alendronate needed to prevent or lessen the severity of bone loss associated with rheumatoid arthritis.

"Therapeutically effective amount"--the amount of alendronate needed to treat bone loss associated with rheumatoid
25 arthritis.

In a preferred aspect of this invention, the patient will receive alendronate. Alendronate may be prepared according to any of the processes described in U.S. Patents 5,019,651, 4,992,007, and U.S. Application Serial No. 08/286,151, filed August 4, 1994, each of which
30 is hereby incorporated by reference. The pharmaceutically acceptable salts of alendronate include salts of alkali metals (e.g., Na, K), alkaline earth metals (e.g. Ca), salts of inorganic acids, such as HCl and salts of organic acids such as citric acid and amino acids. Sodium salt forms are preferred, particularly the monosodium salt trihydrate form.

- 3 -

Many of the bisphosphonate compounds of the present invention can be administered in oral dosage forms such as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, paste, tinctures, suspensions, syrups, emulsions, and zydis. Likewise they may be administered in an intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the bisphosphonate compound desired can be used as an agent which treats or prevents bone loss associated with RA.

The dosage regime utilizing the claimed method is selected in accordance with a variety of factors including type, age, weight, sex, and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed. An ordinarily skilled physician or clinician can readily determine and prescribe the effective amount of the drug required to prevent and or treat bone loss.

Oral dosages of the present invention when alendronate is the bisphosphonate will range from between 0.05 mg per kg of body weight per day (mg/kg/day) to about 1.0 mg/kg/day. Preferred oral dosages in humans may range from daily total dosages of about 2.5-50 mg/day over the effective treatment period, and a preferred amount is 5, 10 or 20 mg/day.

Alendronate may be administered in a single daily dose or in a divided dose. It is desirable for the dosage to be given in the absence of food, preferably from about 30 minutes to 2 hours prior to a meal, such as breakfast to permit adequate absorption.

In the methods of the present invention, the active ingredient is typically administered in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as "carrier materials") suitably selected with respect to the intended form of administration, i.e. oral tablets, capsules, elixirs, syrups and the like and consistent with conventional pharmaceutical

- 4 -

practices. For example, for oral administration in the form of a tablet or capsule, the active ingredient can be combined with an oral, non-toxic, pharmaceutically acceptable inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, croscarmellose sodium and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture of active ingredient(s) and inert carrier materials. Suitable binders may include starch, gelatin, natural sugars such as glucose, anhydrous lactose, free-flow lactose, beta-lactose, and corn sweeteners, natural and synthetic gums, such as acacia, tragacanth or sodium alginate, carboxymethyl cellulose, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. A particularly preferred tablet formulation of alendronate is that described in U.S. Patent 5,358,941, which is hereby incorporated by reference.

The compounds used in the instant method may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran co-polymer, polyhydroxylpropyl-methacrylamide and the like.

Patients suffering from rheumatoid arthritis may be male or female of any age. Women may be pre-or post-menopausal.

The following non-limiting examples are presented to better illustrate the invention.

- 5 -

EXAMPLE 1

Alendronate for the treatment and prevention of bone loss in patients with rheumatoid arthritis

5 220 men and women with active rheumatoid arthritis (as defined by the 1987 ARA Diagnostic Criteria), ages 18-80 are studied in a randomized double-blind clinical trial. Patients are randomized into 5 groups which receive either placebo, 2.5, 5, 10, or 20 mg/day alendronate orally each day for one year. In addition to standard RA
10 therapy, patients are also given 1000 mg calcium and 250 IU Vitamin D daily.

 After one year, the bone mineral density (BMD) of the spine, hip and total body are measured. In addition, the hand erosion score is assessed using standard techniques.

15 It is found that patients who receive daily oral alendronate at doses of 5-20 mg/day increase spine and hip BMD relative to both their baseline scores and to patients receiving placebo. The increase is statistically significant. Also, in patients receiving alendronate, hand erosion scores are decreased relative to baseline and placebo.

- 6 -

WHAT IS CLAIMED IS:

1. A method of preventing or treating generalized and/or periarticular bone loss associated with rheumatoid arthritis (RA) comprising administering an effective amount of a bisphosphonate selected from the group consisting of: alendronate (4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid), etidronate (1-hydroxy-ethidene-bisphosphonic acid), pamidronate (3-amino-1-hydroxy-propyldiene-1,1-diphosphonate), risedronate (2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonic acid), clodronate (dichloromethylene-bisphosphonic acid), tiludronate (chloro-4-phenylthio-methylidene-bisphosphonic acid), ibandronic acid (1-hydroxy-3(methylpentylamino)-propylidene-bisphosphonic acid, and pharmaceutically acceptable salts of any of the foregoing, and mixtures of any of the acids and any of the salts to a patient suffering from RA.
2. A method according to Claim 1 wherein the bisphosphonate is alendronate.
3. A method according to Claim 2 wherein the alendronate is in the form of monosodium salt trihydrate.
4. A method according to Claim 3 wherein the alendronate is administered orally.
5. A method according to Claim 3 wherein the alendronate is administered in a dose of from 2.5 to 50 mg per day.
6. A method according to Claim 5 wherein the alendronate is administered in a dose of 5 mg, 10 mg, or 20 mg per day.

- 7 -

7. A method of treating bone loss associated with rheumatoid arthritis (RA) comprising administering a therapeutically effective amount of alendronate or a pharmaceutically acceptable salt thereof to a patient suffering from RA.

5

8. A method according to Claim 7 wherein the alendronate is in the form of monosodium salt trihydrate.

9. A method according to Claim 8 wherein the
10 alendronate is administered orally.

10. A method according to Claim 8 wherein the alendronate is administered in a dose of from 2.5 to 50 mg per day.

11. A method according to Claim 10 wherein the
15 alendronate is administered in a dose of 5 mg, 10 mg, or 20 mg per day.

12. A method of preventing bone loss associated with rheumatoid arthritis (RA) comprising administering a therapeutically
20 effective amount of alendronate or a pharmaceutically acceptable salt thereof to a patient suffering from RA.

13. A method according to Claim 12 wherein the alendronate is in the form of monosodium salt trihydrate.

25

14. A method according to Claim 13 wherein the alendronate is administered orally.

15. A method according to Claim 13 wherein the
30 alendronate is administered in a dose of from 2.5 to 50 mg per day.

16. A method according to Claim 15 wherein the alendronate is administered in a dose of 5 mg, 10 mg, or 20 mg per day.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/08361

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 31/66, 31/685

US CL :514/108

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/108

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	US 5,462,932 A (BRENNER ET AL) 31 October 1995, see claim 21.	1-16

☐

Further documents are listed in the continuation of Box C.

☐

See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

28 JUNE 1996

Date of mailing of the international search report

01 AUG 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

FREDERICK KRASS

Telephone No. (703) 308-2351

Ann Ital Med Int 1992 Jul-Sep;7(3 Suppl):158S-165S

Clinical trials with bisphosphonates.

Lombardi A, Santora AC.

Clinical Research-Endocrinology and Metabolism, Merck Research Laboratories, Rahway, NJ.

Bisphosphonates are nonbiodegradable pyrophosphate analogs that are capable of inhibiting bone resorption in vivo and in vitro. For this reason they have been used as effective therapeutic agents in several conditions characterized by increased bone turnover, including Paget's disease, hypercalcemia of malignancy, and metastatic bone disease. More recently, bisphosphonates have been proposed for the treatment and prevention of bone loss in several forms of osteoporosis. Etidronate, the first bisphosphonate to be used in clinical trials, has been found to increase vertebral bone mineral mass in osteoporotic patients. However, the gain in bone mass reaches a plateau after 1-2 years of treatment, with no further increase thereafter. No positive effect on osteoporotic fracture rate has been clearly demonstrated. Moreover, etidronate has been shown to impair bone formation and mineralization at therapeutic doses.

Newer, more potent bisphosphonates selectively inhibit bone resorption without impairing bone histology and mechanical strength. Pamidronate has been shown to increase vertebral bone mass in patients with steroid-induced osteoporosis and involutional osteoporosis. In the latter group, this increase did not plateau and was found to be sustained for at least 4 years. However, pamidronate use is associated with relatively poor gastrointestinal tolerability. The use of another agent, clodronate, has been limited by the possible link with the onset of hematologic malignancies. Alendronate is another agent which in studies to date has been found to increase vertebral bone mass in postmenopausal patients. Alendronate also seems to be more potent and better tolerated than pamidronate. (ABSTRACT TRUNCATED AT 250 WORDS)